Loading…
Loading…
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation.
California State Teachers Retirement System lifted its holdings in Pfizer Inc. (NYSE: PFE) by 2,320.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,981,455 shares of the biopharmaceutical company's stock after purchasing an additional 208,976,273 shares during the quarter. California State
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
Five S&P 500 stocks—VICI, PFE, VZ, T, F—offer 'safer' high yields, with free cash flow covering dividends and dividends from $1K invested exceeding share prices. Analyst projections indicate the top ten S&P 500 dividend dogs could deliver average net gains of 24.11% by September 2027, with risk/volatility 36% below the market. Dividend dog strategy favors contrarian buys on price pullbacks; most top-yielding stocks become attractive as market corrections bring yields in line with share prices.
It also advanced a pair of promising developmental drugs. Investors have grown impatient waiting for the company's next blockbuster product.
Pharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer. Pfizer faces greater exposure this decade to the loss of patent exclusivity for its blockbuster drugs.